3
Participants
Start Date
April 28, 2017
Primary Completion Date
March 8, 2022
Study Completion Date
March 8, 2022
Stereotactic Body Radiotherapy
"All patients in this trial will be treated with fractionated Stereotactic body radiation therapy.~SBRT will be delivered to \<=3 sites in 3-5 fractions followed by administration of the specified immunotherapy agent (Nivolumab or Pembrolizumab). This approach will take advantage of the transient increase in antigen availability, increased antigen presentation and upregulation of PD-1 by tumor cells following ablative radiation therapy."
Philadelphia CyberKnife, Philadelphia
Saint Peters University Hospital
OTHER
Community Medical Center, Toms River, NJ
OTHER
Crozer-Keystone Health System
OTHER